C5 Inhibition in Secondary Thrombotic Microangiopathies: A Yet Unresolved Question

被引：2
|
作者：
Werion, Alexis [1 ]
Rondeau, Eric [1 ]
机构：
[1] Hop Tenon, AP HP, Intens Care Nephrol & Transplantat Dept, SINRA, Paris, France
来源：
KIDNEY INTERNATIONAL REPORTS | 2021年 / 6卷 / 04期
关键词：
COMPLEMENT INHIBITORS;
D O I：
10.1016/j.ekir.2021.02.012
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：878 / 880
页数：3
相关论文
共 50 条
  • [41] INHIBITION OF CLASSICAL C5 CONVERTASE IN THE COMPLEMENT-SYSTEM BY FACTOR-H
    ITO, S
    TAMURA, N
    IMMUNOLOGY, 1983, 50 (04) : 631 - 635
  • [42] Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point
    Hilton, Emma C. Y.
    Baverel, Paul G.
    Woodcock, Ashley
    Van der Graaf, Piet H.
    Smith, Jaclyn A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (04) : 847 - +
  • [43] INHIBITION OF C5 CONVERTASE BY EPSILON AMINO CAPROIC ACID (EACA) - LIMITING FACTOR IN GENERATION OF C5A ANAPHYLATOXIN
    VALLOTA, EH
    IMMUNOLOGY, 1978, 34 (03) : 439 - 447
  • [44] Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine
    Sheikhnejad, G
    Brank, A
    Christman, JK
    Goddard, A
    Alvarez, E
    Ford, H
    Marquez, VE
    Marasco, CJ
    Sufrin, JR
    O'Gara, M
    Cheng, XD
    JOURNAL OF MOLECULAR BIOLOGY, 1999, 285 (05) : 2021 - 2034
  • [45] Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity
    Mannes, Marco
    Dopler, Arthur
    Zolk, Oliver
    Lang, Sophia J.
    Halbgebauer, Rebecca
    Hoechsmann, Britta
    Skerra, Arne
    Braun, Christian K.
    Huber-Lang, Markus
    Schrezenmeier, Hubert
    Schmidt, Christoph Q.
    BLOOD, 2021, 137 (04) : 443 - 455
  • [46] Complement Inhibition at the Level of C3 or C5: Mechanistic Reasons for Ongoing Terminal Pathway Activity
    Mannes, M.
    Dopler, A.
    Zolk, O.
    TRANSPLANTATION, 2021, 105 (04) : 679 - 680
  • [47] Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19
    Zelek, Wioleta M.
    Cole, Jade
    Ponsford, Mark J.
    Harrison, Richard A.
    Schroeder, Ben E.
    Webb, Nicholas
    Jolles, Stephen
    Fegan, Christopher
    Morgan, Matt
    Wise, Matt P.
    Morgan, B. Paul
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 202 (09) : 1304 - 1308
  • [48] Real-world experience with C5 complement inhibition and FcRn modulation in myasthenia gravis
    Huntemann, N.
    Nelke, C.
    Schroeter, C.
    Meuth, S.
    Ruck, T.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [49] Complement C5 inhibition with eculizumab/ravulizumab in kidney transplant patients - A single center experience
    Borstnar, Spela
    Haler, Zeljka Veceric
    Mlinsek, Gregor
    Arnol, Miha
    Kouter, Katarina
    Simcic, Sasa
    Rigler, Andreja Ales
    TRANSPLANTATION, 2024, 108 (9S)
  • [50] Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5
    Latuszek, Adrianna
    Liu, Yashu
    Olsen, Olav
    Foster, Randi
    Cao, Marc
    Lovric, Irena
    Yuan, Ming
    Liu, Nina
    Chen, Henry
    Zhang, Qian
    Xiao, Hui
    Springer, Carola
    Ehrlich, George
    Kamat, Vishal
    Rafique, Ashique
    Hu, Ying
    Krueger, Pamela
    Huang, Tammy
    Poueymirou, William
    Babb, Robert
    Rosconi, Michael P.
    Retter, Marc W.
    Chen, Gang
    Morton, Lori
    Zambrowicz, Brian
    Cao, Jingtai
    Romano, Carmelo
    Olson, William C.
    PLOS ONE, 2020, 15 (05):
12345